PDCD1 and classic Hodgkin lymphoma: Pembrolizumab and nivolumab, anti-PD-1 antibodies, have demonstrated remarkable efficacy in relapsed or refractory cHL, leading to durable responses in a significant proportion of patients (14, 15).